Return to QS17 Overview

Lung cancer in adults [QS17]

Measuring the use of this guidance

Statement: 4

People with known or suspected lung cancer have access to a named lung cancer clinical nurse specialist who they can contact between scheduled hospital visits.

Quality standard measure: Proportion of people with lung cancer who had a lung cancer clinical nurse specialist present at diagnosis.
What was measured: Seen by lung cancer nurse specialist
Data collection end: December 2014
78%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who had a lung cancer clinical nurse specialist present at diagnosis.
What was measured: Seen by lung cancer nurse specialist.
Data collection end: December 2014
77.5%
Data collection end: December 2015
54.8%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who had a lung cancer clinical nurse specialist present at diagnosis.
What was measured: Lung cancer nurse specialist present at diagnosis (England only).
Data collection end: December 2016
57.8%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who had a lung cancer clinical nurse specialist present at diagnosis.
What was measured: Proportion of people with lung cancer who had a lung cancer clinical nurse specialist present at diagnosis.
Data collection end: August 2018
58%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who have been assessed by a lung cancer clinical nurse specialist.
What was measured: Assessed by lung cancer nurse specialist (England only).
Data collection end: December 2016
70.3%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who have been assessed by a lung cancer clinical nurse specialist.
What was measured: Proportion of people with lung cancer who were assessed by a lung cancer nurse specialist.
Data collection end: August 2018
70%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with known or suspected lung cancer who have been given the name and contact number of a lung cancer clinical nurse specialist who they can contact between scheduled hospital visits.
What was measured: Proportion of lung cancer patients who reported that they were given the name of a Clinical Nurse Specialist who would support them through their treatment.
Data collection end: June 2015
93.4%
Data collection end: June 2016
93.8%
Data collection end: March 2018
94.1%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

Quality standard measure: Patient satisfaction with access to and support from a lung cancer clinical nurse specialist.
What was measured: Proportion of lung cancer patients who reported that they found it easy to contact their Clinical Nurse Specialist.
Data collection end: June 2015
88.5%
Data collection end: June 2016
87.6%
Data collection end: March 2018
86.7%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

Quality standard measure: Patient satisfaction with access to and support from a lung cancer clinical nurse specialist.
What was measured: Proportion of lung cancer patients who reported that, when they had important questions to ask their Clinical Nurse Specialist, they got answers they could understand.
Data collection end: June 2015
88.7%
Data collection end: June 2016
88.2%
Data collection end: March 2018
86.9%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Statement: 5

People with lung cancer are offered a holistic needs assessment at each key stage of care that informs their care plan and the need for referral to specialist services.

Quality standard measure: Patient satisfaction with support offered.
What was measured: Proportion of lung cancer patients who reported that staff gave them information about support or self-help groups for people with cancer.
Data collection end: June 2015
82.4%
Data collection end: June 2016
82.6%
Data collection end: March 2018
85.2%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

Quality standard measure: Patient satisfaction with support offered.
What was measured: Proportion of lung cancer patients who reported that staff gave them information about how to get financial help or any benefits they might be entitled to.
Data collection end: June 2015
68.1%
Data collection end: June 2016
68.5%
Data collection end: March 2018
68.9%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.

Quality standard measure: Patient satisfaction with support offered.
What was measured: Proportion of lung cancer patients who said that they were given enough care and support from health or social services if required (for example district nurses, home helps, physiotherapy).
Data collection end: June 2015
51.8%
Data collection end: June 2016
50.1%
Data collection end: March 2018
51.4%
Area covered: England
Source: Quality Health. National Cancer Patient Experience Survey.


Statement: 6

People with lung cancer, following initial assessment and computed tomography (CT) scan, are offered investigations that give the most information about diagnosis and staging with the least risk of harm.

Quality standard measure: Proportion of people with lung cancer following initial assessment and CT scan who receive two or more invasive tests for diagnostic and staging purposes.
What was measured: Proportion of patients receiving a histological / cytological diagnosis.
Data collection end: December 2014
69%
Data collection end: December 2015
72.5%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Histological confirmation rate.
What was measured: Proportion of people with lung cancer receiving a histological diagnosis
Data collection end: December 2014
69%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Statement: 7

People with lung cancer have adequate tissue samples taken in a suitable form to provide a complete pathological diagnosis including tumour typing and sub-typing, and analysis of predictive markers.

Quality standard measure: Proportion of people with lung cancer who have a pathological diagnosis.
What was measured: Proportion of people with lung cancer receiving a histological diagnosis.
Data collection end: December 2014
69%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who have a pathological diagnosis.
What was measured: Proportion of people with stage I–II lung cancer who have a performance status of 0–1 and receive pathological diagnosis.
Data collection end: August 2018
89%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Statement: 9

People with lung cancer are offered assessment for multimodality treatment by a multidisciplinary team comprising all specialist core members.

Quality standard measure: % small cell receiving chemotherapy
What was measured: Percentage of patients with small cell lung cancer receiving chemotherapy
Data collection end: December 2014
67.9%
Number that met the criteria: 2072 / 3052
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Chemotherapy rate for stage IIIB and IV (performance status 0 and 1) non-small-cell lung cancer.
What was measured: Chemotherapy Rate in IIIB/IV PS 0-1 NSCLC
Data collection end: December 2014
57.3%
Number that met the criteria: 3014 / 5260
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Chemotherapy rate for stage IIIB and IV (performance status 0 and 1) non-small-cell lung cancer.
What was measured: Proportion of patients with stage IIIB/IV, performance status 0-1, NSCLC who had chemotherapy (England only).
Data collection end: December 2016
62.5%
Number that met the criteria: 4214 / 6746
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Overall active treatment rates.
What was measured: Proportion of lung cancer patients receiving anti cancer treatment
Data collection end: December 2014
57.6%
Number that met the criteria: 16125 / 27995
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Overall active treatment rates.
What was measured: Proportion of lung cancer patients receiving anti cancer treatment (England only).
Data collection end: December 2016
58.2%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Radiotherapy rates.
What was measured: Proportion of patients receiving radiotherapy (England only).
Data collection end: December 2016
27.7%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Surgery rates
What was measured: Proportion of patients receiving surgery
Data collection end: December 2014
15.4%
Number that met the criteria: 4059 / 27995
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Surgery rates
What was measured: Proportion of patients receiving surgery (England only).
Data collection end: December 2016
16.8%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Proportion of people with lung cancer who receive assessment for multimodality treatment by a multidisciplinary team comprising all specialist core members.
What was measured: Proportion of people with lung cancer discussed at a multidisciplinary team.
Data collection end: December 2014
94%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.

Quality standard measure: Chemotherapy rate for small-cell lung cancer
What was measured: Proportion of patients with small-cell lung cancer receiving chemotherapy (England only).
Data collection end: December 2016
68%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Statement: 12

People with stage IIIB or IV non‑small‑cell lung cancer are offered systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Quality standard measure: Proportion of people with stage IIIB or IV non‑small‑cell lung cancer who receive systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.
What was measured: Proportion of people with stage IIIB–IV IIIB or IV non‑small‑cell lung cancer who received systemic therapy treatment.
Data collection end: August 2018
66%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Statement: 13

People with small-cell lung cancer have treatment initiated within 2 weeks of the pathological diagnosis.

Quality standard measure: Proportion of people with small-cell lung cancer who have treatment initiated within 2 weeks of the pathological diagnosis.
What was measured: Proportion of people with small-cell lung cancer who receive chemotherapy within 14 days of diagnosis (England only.)
Data collection end: December 2016
33.2%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.



 Return to QS17 Overview